DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Dacetuzumab is an investigational drug.
There have been 7 clinical trials for Dacetuzumab. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2006.
The most common disease conditions in clinical trials are Lymphoma, Non-Hodgkin, Lymphoma, and Lymphoma, Large B-Cell, Diffuse. The leading clinical trial sponsors are Seattle Genetics, Inc., Genentech, Inc., and [disabled in preview].
Recent Clinical Trials for Dacetuzumab
|Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL||Genentech, Inc.||Phase 1|
|Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL||Seattle Genetics, Inc.||Phase 1|
|A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL||Genentech, Inc.||Phase 2|